Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This is an open-label, Phase 1/2a dose escalation study with an expansion phase to evaluate
the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD), and preliminary
efficacy of CORT125281 in combination with enzalutamide in patients with metastatic
castration-resistant prostate cancer (mCRPC) to identify a recommended dose (RD) for Phase 2
studies.